Type 2 Diabetes is Cardiovascular Disease

Kwiatkowski T.G. , Libman R.B. , Frankel M. . Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340: 1781–7

Brown M.M. Brain attack: a new approach to stroke. Clin Med 2002; 2: 60–5

Kannel W.B. , McGee D.L. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035–8

Saydah S.H. , Eberhardt M.S. , Loria C.M. , Brancati F.L. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002; 156: 714–19

Harris M.I. , Klein R. , Welborn T.A. , Knuiman M.W. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815–19

Turner R.C. , Millns H. , Neil H.A. . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8

Position Statement by the American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care 2003; 26: S73–7

Tuomilehto J. , Lindstrom J. , Eriksson J.G. . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

Position Statement by the American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003; 26: S87–8

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

Position Statement by the American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26: S83–6

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–9

Gaede P. , Vedel P. , Larsen N. . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–10

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

Chobanian A.V. , Bakris G.L. , Black H.R. . The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560–71

Colagiuri S, Cull CA, Holman RR, the UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: United Kingdom Prospective Diabetes Study 61. Diabetes Care 2002; 25: 1410–17

Rubins H.B. , Robins S.J. , Collins D. . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–18

Goldberg R.B. , Mellies M.J. , Sacks F.M. . Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513–19

Zimmet P. , Alberti K.G. , Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–7